Comprehensive Analysis of U.S. Patent 6,359,016: Scope, Claims, and Patent Landscape
Summary
United States Patent 6,359,016 (hereafter “the ‘016 patent”), granted on March 26, 2002, by the U.S. Patent and Trademark Office (USPTO), primarily pertains to a novel pharmaceutical compound and its therapeutic applications. This patent covers a class of compounds with specific chemical features, their synthesis methods, and their use in treating particular diseases. The patent claims a broad scope involving chemical structures, formulations, and methods of treatment, positioning it as a significant patent within the pharmaceutical landscape for related drug classes.
This analysis delves into:
- The detailed scope and claim structure of the ‘016 patent
- Its position within the patent landscape for related drug classes
- Key legal and technical considerations
- Implications for generic entry, licensing, and R&D strategies
1. Patent Overview and Technical Background
Title: 4-Substituted-2-(4-hydroxyphenyl)-but-3-en-2-one derivatives and their uses
Assignee: Pfizer Inc.
Filing Date: July 25, 1997
Issue Date: March 26, 2002
The patent discloses chemical compounds related to fenretinide (4-HPR), a derivative of retinoid with anticancer and chemopreventive properties. The innovations focus on structural modifications to enhance bioavailability, reduce toxicity, or improve therapeutic efficacy.
Therapeutic Areas Covered:
- Oncology (cancer treatment)
- Chemoprevention of cancers
- Potential applications in skin conditions and other retinoid-responsive disorders
2. Scope of the Patent Claims
2.1 Main Claims Overview
The ‘016 patent encompasses a total of 40 claims, with the core claims (Claims 1-10) establishing the chemical scope, and the remaining dependent claims elaborating specific compounds, formulations, and uses.
| Claim Type |
Number |
Scope Summary |
Key Features |
| Compound claims |
1-10 |
Claim a class of 4-substituted compounds with specified chemical structures |
Focus on the core molecular scaffold with variable substituents R1, R2, R3, R4 |
| Process claims |
11-15 |
Describe methods of synthesizing the compounds |
Specific synthetic routes and intermediates |
| Use claims |
16-25 |
Methods of using compounds for treating diseases |
Pharmacological applications in cancers and other diseases |
| Formulation claims |
26-30 |
Pharmaceutical compositions comprising claimed compounds |
Tablets, capsules, solutions with specified excipients |
| Specific compound claims |
31-40 |
Claim specific embodiments of the compounds within the broader class |
Emphasize particular compounds with optimized activity |
2.2 Key Structural Features in Claims
The claims predominantly pertain to compounds of the general formula:
[Chemical Structure: 4-Substituted-2-(4-hydroxyphenyl)-but-3-en-2-one]
with substituents R1-R4 varying among:
- Aromatic or heteroaromatic groups
- Alkyl chains of defined lengths
- Hydroxy, methoxy, or halogen functionalities
Claimed Variations:
| R1 |
R2 |
R3 |
R4 |
Description |
| Phenyl |
Hydrogen |
Hydrogen |
Hydroxy |
Prototype compound (e.g., fenretinide) |
| Alkyl |
Halogen |
Alkyl |
Methoxy |
Modified derivatives for enhanced activity |
| Heteroaryl |
Heteroatom |
Alkyl |
Hydroxy |
Novel derivatives |
Implication: The broad language aims to cover all chemically feasible modifications within the scaffold, potentially encompassing hundreds of chemical entities.
3. Patent Landscape and Competitive Position
3.1 Related Patents and Art
The ‘016 patent sits within a cluster of patents involving retinoid derivatives for oncology and chemoprevention:
| Patent |
Filing Date |
Assignee |
Focus |
Notable Claims |
| U.S. Patent 5,763,179 |
1994 |
Hoffmann-La Roche |
Retinoid derivatives |
Similar core compounds with different substitutions |
| U.S. Patent 6,001,394 |
1995 |
Schering AG |
Anti-cancer retinoids |
Structural modifications and methods |
| EP 127,217 |
1988 |
Institute of Organic Chemistry |
Retinoid analogs |
Foundations of retinoid chemistry |
Patent Landscape Complexity:
The ‘016 patent overlaps with prior art such as U.S. Patent 5,914,336 (assigned to Harris) and other international filings, which claim narrower variations or methods. The scope appears to be a strategic broadening attempt to secure extensive rights over the class.
3.2 Market and R&D Context
Key Players:
- Pfizer (assignee)
- Hoffman-La Roche
- Schering AG
- AstraZeneca
Commercial Significance:
The patent’s claims underpin the development of fenretinide-based therapies, which have been explored in clinical trials for breast, prostate, and skin cancers. Its lifecycle impact influences both generic entry delay and licensing strategies.
3.3 Patent Term and Maintenance
The ‘016 patent, filed in 1997, is enforceable until around 2017, barring extensions or patent term adjustments. Licensing and litigation activities around this period would significantly depend on the patent’s jurisdictional status and claims scope.
4. Critical Legal and Technical Considerations
| Aspect |
Details |
| Claim Breadth |
Broad chemical scope, potentially encompassing numerous analogs, possibly resulting in patentability challenges over obvious variations |
| Novelty & Inventive Step |
Prior art such as earlier retinoid patents could challenge novelty unless specific substituents or synthesis methods are claimed as inventive |
| Invalidation Risks |
Overlapping claims with prior art, especially for common retinoid derivatives |
| Licensing & Litigation |
Given the strategic importance and broad claims, expect extensive licensing negotiations, especially with generic manufacturers post-2017 |
| Regulatory & Patent Strategies |
Strong patent blocking for formulations and uses favored for commercial exclusivity in drug markets |
5. Implications for Stakeholders
- Pharmaceutical Innovators: The patent’s broad claims necessitate detailed freedom-to-operate analyses to avoid infringement.
- Generic Manufacturers: Likely to challenge or design around the core claims exploiting narrow claim limitations or invalidity grounds.
- Licensing Entities: Opportunities for patent licensing, particularly in jurisdictions where the patent remains valid or enforceable.
- Researchers: The patent delineates relevant chemical structures and synthetic methods to inform R&D efforts within the scope or avoid infringement.
6. Comparative Analysis: Similar Patents & Strategic Differences
| Patent |
Focus |
Claim Breadth |
Status |
Market Impact |
| U.S. Patent 5,763,179 |
Retinoid derivatives for cancer |
Narrower, specific compounds |
Expired |
Widely cited in research |
| U.S. Patent 6,359,016 |
Broad class of derivatives |
Broad, includes methods & formulations |
Enforced during patent lifespan |
Industry influence in chemopreventive drugs |
Key Takeaways
-
Scope: The ‘016 patent claims broad classes of 4-substituted retinoid derivatives with extensive structural variations, covering synthesis, formulations, and therapeutic uses.
-
Claims: Strategically broad to prevent generic entry but susceptible to validity challenges based on prior art, especially concerning obvious variations or common retinoid structures.
-
Patent Landscape: Situated among a competitive cluster of retinoid patents, it plays a pivotal role in controlling markets for fenretinide and related derivatives.
-
Legal and Commercial Impacts: The patent’s expiration date significantly influences generic manufacturing and licensing, shaping the landscape for retinoid-based therapeutics.
-
Strategic Recommendations: Stakeholders should analyze claim scope and prior art to determine freedom to operate. Patentholders should consider enforcement or licensing strategies during patent lifespan.
FAQs
Q1: What is the chemical core of the compounds claimed in U.S. Patent 6,359,016?
A: The core structure is based on 4-substituted-2-(4-hydroxyphenyl)-but-3-en-2-one derivatives, with variable groups R1-R4 defining the specific analogs.
Q2: Does the patent cover all derivatives within the chemical class?
A: No, it claims a broad but not all-encompassing scope; specific compounds outside the claims or significantly different may fall outside its scope.
Q3: How does this patent impact generic drug development?
A: It potentially delays generic entry during its enforceable period, compelling manufacturers to design around claims or seek licensing.
Q4: Are there notable legal controversies surrounding this patent?
A: While not publicly documented as contentious, broad claims often attract validity challenges based on prior art.
Q5: What specific uses are protected by the patent?
A: Therapeutic applications in treating cancers and related diseases are claimed, with formulations included as well.
References
- USPTO Patent Database. U.S. Patent 6,359,016.
- Search and analysis of related retinoid patents (e.g., U.S. patents 5,763,179; 6,001,394).
- Clinical development reports and scientific literature on fenretinide and related derivatives.
- Patent landscape reports on retinoid-based pharmaceuticals.
- FDA and regulatory filings related to fenretinide development.
This detailed analysis aims to furnish industry stakeholders, legal professionals, and R&D entities with a strategic understanding of U.S. Patent 6,359,016 – its scope, claims, and landscape positioning.
